Case Reports

Renal Replacement Therapy in a Patient Diagnosed With Pancreatitis Secondary to Severe Leptospirosis

Author and Disclosure Information

 

References

Conclusions

LS continues to be of interest due to its current status as the most common zoonotic disease and its widespread prevalence throughout the globe. Novel treatment modalities for LS, specifically for Weil disease, continue to be developed with the goal of reducing the current mortality rate associated with the disease.

In endemic areas, prompt recognition is essential to initiate the recommended therapy. Parenteral antibiotics, such as penicillin G sodium and ceftriaxone, continue to be the mainstay of treatment and constitute the current CDC recommendations. Nonetheless, early initiation of CRRT has been shown to greatly reduce the mortality associated with Weil disease and, when available, should be considered in these patients.

Our patient failed to improve while receiving parenteral antibiotics alone but showed marked improvement after being placed on CRRT. Furthermore, initiation of CRRT resulted in near-complete resolution of his organ dysfunction and eventual discharge from the hospital. This case serves to further support the use of early CRRT as part of the standard of care in severe LS.

Pages

Recommended Reading

Non–COVID-19 VA Hospital Admissions Drop During the Pandemic
Federal Practitioner
US News releases latest top hospitals list, adds COVID heroes
Federal Practitioner
When you see something ...
Federal Practitioner
Creating an Intensive Care Unit From a Postanesthesia Care Unit for the COVID-19 Surge at the Veterans Affairs Ann Arbor Healthcare System
Federal Practitioner
Implementation of a Protocol to Manage Patients at Risk for Hospitalization Due to an Ambulatory Care Sensitive Condition
Federal Practitioner
Chronic Microaspiration and Frailty: A Geriatric Smoking Gun?
Federal Practitioner
An Atypical Long-Term Thiamine Treatment Regimen for Wernicke Encephalopathy
Federal Practitioner
FIT unfit for inpatient, emergency settings
Federal Practitioner
Guideline Concordance with Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience
Federal Practitioner
Electronic Reminders Extend the Reach of Health Care
Federal Practitioner